Sponsor

Sanofi Vaccines US Inc.

United States 1 Discovery Drive, 18370-9100, United States

About the sponsor

Research activity centers on pneumococcal immunization across infants, toddlers, children, and adolescents, with attention to immune responses against multiple serotypes and the comparative performance of 21-valent formulations.

serotype-specific immunogenicity
opsonophagocytic activity
safety and tolerability
catch-up vaccination

The portfolio includes evaluation of IgG antibody responses and functional antibody activity in pediatric age groups.

About Specializations

Sanofi Vaccines US Inc. runs clinical trials in conditions such as Pneumococcal immunisation, Immunisation, Influenza immunisation, COVID-19 immunisation, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

7 clinical trials

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Not yet recruiting

Investigational

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational

Czechia

Participants:18–64 years · 65+ years · Healthy volunteers
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational

Germany

Participants:18–64 years
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo

Estonia

Participants:0–17 years · Healthy volunteers
Substances:Pneumococcal polysaccharide serotype 1
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational

Finland

Participants:0–17 years · Healthy volunteers
Substances:534
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Meningococcal immunisation

Not recruiting

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo